The Road To ‘Personalised Medicine’ and the rules of good biobanking with AstraZeneca's Duncan McHale, Vice-President for Personalised Healthcare and Biomarkers

Duncan McHale, Vice-President for Personalised Healthcare and Biomarkers, Astrazeneca, joins Helen Winsor of Pharma IQ. In this interview he discusses the importance of biomarker discovery & validation, how close we are to ‘Personalised Medicine’, why sample quality is key, the rules of good biobanking, how we can improve biomarker research, what we should change and why, what’s stopping us bringing change and his top 3 priorities for the next 12 months.

Please note: That all fields marked with an asterisk (*) are required.

Please Enter Your First Name
Please Enter Your Last Name
Please Enter Your Job Title
Please Enter Your Company Name
Please Enter Your Email Address
Please Enter Your Telephone
Please Select Your Country